Study type · BioequivalenceUpdated October 11, 2026

Bioequivalence study data capture without an enterprise EDC

A bioequivalence study is short, tightly scheduled and unforgiving about times. Capture records the period, sequence, dosing, actual sampling times, safety checks and deviations in one study with an audit trail, then exports clean data for your bioanalytical and pharmacokinetic team. Free sandbox, no credit card.

  • Period and sequence records
  • Actual vs scheduled times
  • Exports for your PK analysts

Free sandbox · No credit card · 21 CFR Part 11 aligned

Two-period crossover capture plan (demo)
AssessmentScreenP1 Day -1P1 Dosing dayP1 Day 2P2 Day -1P2 Dosing dayP2 Day 2Follow-up
Eligibility and consent
Randomized sequence recorded
Dosing record (product, time)
Blood sample times (actual)
Vitals, ECG and adverse events
Safety labs

x = collected at this visit

Demo layout only. Periods, washout, samples and assessments come from your protocol.

What a bioequivalence study needs from data capture

  • Sequence and period as data. In a typical crossover bioequivalence design, each volunteer receives test and reference on separate occasions in a random sequence, so every sample must be tied to the right period and product.
  • Times you can check. Dosing time and each sample time are the inputs for the pharmacokinetic analysis, so scheduled and actual times both belong in the record.
  • Safety in healthy volunteers. Vitals, ECG, labs and adverse events are captured at every period, and unexpected findings need a trail.
  • A boundary with your analysts. Capture holds the clinical data. Concentration data and the statistics sit with your bioanalytical laboratory and your pharmacokineticist; Capture does not perform PK or NCA analysis.
  • Short build, short study. Bioequivalence studies are quick, so the build-test-go-live path in the free sandbox suits them.

The design

What a bioequivalence study asks you to record

A bioequivalence study asks whether two formulations of the same active ingredient deliver it to the bloodstream at a similar rate and extent. The common approach, described in regulatory guidance, compares peak concentration and total exposure for a test and a reference product in healthy subjects, using a 90 percent confidence interval around the ratio of geometric means, usually judged against an 80 to 125 percent limit. The classic design is a randomized crossover: volunteers are assigned to one of the possible sequences, receive the products on separate occasions, and there is a washout between periods. Fed, fasting, replicate and parallel designs exist for particular products, and the protocol, built on current product-specific guidance, decides which applies to you.

None of that analysis happens in an EDC. What an EDC contributes is the integrity of the inputs. If a volunteer was dosed 12 minutes late, or a blood draw was taken outside its window, or the product given in period 2 does not match the assigned sequence, the person who analyses the concentration data needs to know, and the monitor needs to see how it was recorded. So the clinical record is organised around the unit of analysis: volunteer, period, product, nominal time and actual time.

Because the study is short and the analysts work from structured files, a good data capture plan is small. It lists the forms, the key time fields, the checks and the export specification, and does so before the first volunteer is screened. The protocol synopsis generator and equivalence trial sample size calculator help with early planning, and the sample size stays a statistician’s decision.

Why times matter more than visits

In most clinical studies a visit date is enough. In a bioequivalence study the sample draw times are the data. Record the nominal (scheduled) time point, the actual date and time of the draw, and a reason when the actual time falls outside the allowed window. Capture can calculate the minutes between two date-times as a read-only field during entry, so the deviation from nominal is visible immediately; the protocol decides which deviations are acceptable and how they are handled in the analysis.

Blood sample record (demo)
Subject 001-0014 · Period 2 · Sequence TRDraft

Dosing and sample

Product administered

EXTRT
TestReference

Dosing date and time

EXSTDTC
2026-03-11 08:00

Nominal sample time

PCTPT
1 h

Actual draw time

PCDTC
2026-03-11 09:04

Minutes after dosing

PCELTM
64 min Calculated

Outside +/- 2 min window, give reason

Reason for deviation

PCDEVR
Cannula repositioned
Demo data only. Windows and variable names follow your protocol.Save
Deviations are recorded and queried, not silently corrected.

Protocol to build

Bioequivalence study elements and where they live in Capture

Study elementWhat the data looks likeWhere it lives in Capture
Screening and eligibilityHistory, vitals, ECG, labs, inclusion and exclusionEligibility form, medical history, vital signs, lab results
ConsentSigned, countersigned consent before any procedureeConsent
Sequence assignmentRandomized sequence and period orderRandomization in the same study; see randomization software
Dosing recordProduct, dose, date and time, fed or fasted statePer-period eCRF form
Sample collection recordNominal and actual time, sample ID, deviation reasonPer-period eCRF form with calculated minutes after dosing
SafetyVitals, ECG, adverse events, concomitant medicationsAE form, concomitant medications
Data transferClinical data to your analysts and laboratoryCSV or Excel exports with data dictionary; SDTM export

Capture records the clinical data. Bioanalytical concentrations and pharmacokinetic analysis are done outside Capture.

Build the two-period record and test the time checks

Create the dosing and sample forms in the free sandbox, enter practice volunteers across two periods and see how deviations are flagged. No credit card.

Build your BE study free

Safety and quality

Healthy volunteers, short studies, no room for loose data

Volunteers in bioequivalence studies are healthy, so the safety bar and the expectation of clean data are both high. Capture records vitals, ECG and laboratory values with edit checks, range rules and auto-queries when a value breaks a rule. Calculated fields such as QTc by the Bazett or Fridericia formula appear read-only during entry, and the QTc calculator is a quick standalone check if you want one. Adverse events carry severity, seriousness and relationship as separate fields, and the investigator keeps the clinical judgment.

Every change is written to a field-level audit trail with the user, time, old value, new value and reason. For a short study with many time fields, that trail is how a monitor or auditor reconstructs what happened without relying on memory. Forms follow a draft to approved lifecycle and approved forms are locked for live use, so the CRF cannot drift mid-study. The wider compliance picture is on the 21 CFR Part 11 compliant EDC page; Capture provides Part 11-aligned controls and compliance depends on your validated use.

Small clinical units and sponsors running their own studies can keep the clinical data in one place without an enterprise contract. EDC for CRO-independent trials explains how teams run without a CRO.

Build sequence

From BE protocol to first dosed volunteer

  1. 1

    Write the capture spec

    List the forms, time fields, windows and the export layout the analysts expect, with the protocol open.

  2. 2

    Draft the forms

    Upload the protocol for an AI draft of visits and forms, or start from templates. A person reviews everything before it is saved.

  3. 3

    Add the checks

    Range checks on vitals and labs, minutes-after-dosing calculation, required reasons for out-of-window samples.

  4. 4

    Test the full cycle

    Run practice volunteers through both periods and look at the exports in the format your analysts need.

  5. 5

    Approve and go live

    Approve the forms to lock them, start the paid live phase and screen the first volunteer.

Before first volunteer

Bioequivalence capture readiness

Time conventions written

Time zone, clock source and what counts as the actual draw time.

Windows defined

Allowed deviation for each nominal sample time and what happens outside it.

Product coding agreed

How test and reference are identified on the form without unblinding anyone who should not know.

Export layout agreed

The file structure your analysts and laboratory expect.

Sandbox rehearsal done

Clinic staff have entered a full practice period.

FAQ

Questions teams ask before they switch

Something not covered here? Ask us directly.

Does Capture run the pharmacokinetic analysis?

No. Capture records the clinical data, including dosing and sample times, safety and deviations, and exports it. Concentration data and PK or statistical analysis are handled by your laboratory and analysts.

Can Capture record the crossover sequence and period?

Yes. Randomization and eCRF forms are in the same platform, so the assigned sequence and each period’s product and times can be recorded and checked. The schedule and washout rules come from your protocol.

How are out-of-window sample times handled?

A calculated field shows minutes between two date-times, an edit check can flag values outside your window, and a reason for the deviation is captured. How deviations are treated in the analysis is your protocol’s decision.

Can we export for the statistician?

Yes. CSV and Excel exports include an automatic data dictionary, and SDTM datasets can be exported as SAS XPT with Define-XML.

Is Capture suitable for a small CRO or clinical unit?

Yes. It is self-serve, so you can build and test in the free sandbox before paying to go live. See the pricing page.

Capture the times your analysts rely on

Build and test your bioequivalence study in the free sandbox. No credit card, and you pay only when volunteers are enrolled.

Build your BE study free